Does AE1/AE3 Positive Mean Cancer?

A positive AE1/AE3 result on a pathology report does not, by itself, mean cancer. AE1/AE3 is a cocktail of antibodies that detects cytokeratins, structural proteins found in virtually all epithelial cells, whether healthy or malignant. Normal skin, breast ducts, the lining of your gut, and mesothelial cells coating your lungs all stain positive for AE1/AE3 because they all contain cytokeratins. The stain tells a pathologist that a cell is epithelial in origin, not that it is cancerous, and the distinction between those two conclusions matters enormously for what comes next.

What AE1/AE3 Actually Detects

Cytokeratins are proteins that form part of the internal scaffolding of cells. They belong to a family called intermediate filaments, which have long been understood as mechanical components that help cells resist physical stress and hold their shape.¹ There are dozens of different cytokeratin subtypes, and different tissues express different combinations of them. AE1 and AE3 are two monoclonal antibodies that, when used together as a cocktail, cover a broad range of these subtypes. AE1 recognizes a group of acidic (type I) cytokeratins, while AE3 targets basic and neutral (type II) cytokeratins. Together, they catch most cytokeratin-expressing cells in a tissue sample.

This broad coverage is the point. Pathologists use AE1/AE3 as a screening stain when they need to answer a basic first question: is this cell epithelial? If the answer is yes, more specific markers follow. If the answer is no, the diagnostic workup branches in a completely different direction. Think of it less as a cancer test and more as a cell-identity test.

Why Normal Tissues Stain Positive

Because cytokeratins are a normal component of epithelial cells, healthy tissues routinely light up with AE1/AE3. In normal breast tissue, for instance, both AE1 and AE3 react strongly with the luminal cells lining ducts and milk-producing glands.² Your skin, your intestinal lining, your bladder lining, and the mesothelial layer around your lungs all express cytokeratins as part of their normal biology.

This is why a positive AE1/AE3 result cannot be read in isolation. If a pathologist biopsies a lump and the cells stain positive for AE1/AE3, the result confirms that the cells are epithelial. Whether they are normal, part of a benign growth, or malignant depends on how the cells look under the microscope and what other markers show up on additional testing.

When AE1/AE3 Positivity Points Toward Cancer

Where AE1/AE3 becomes diagnostically powerful is not in a straightforward biopsy of an obvious mass but in situations where the identity of a suspicious cell is ambiguous. The most common scenario involves lymph nodes. When surgeons remove lymph nodes near a tumor, pathologists examine them for signs that cancer has spread. Standard staining sometimes misses tiny deposits of tumor cells. AE1/AE3 immunohistochemistry can reveal isolated cancer cells or small clusters that would otherwise be invisible. In one study of colorectal cancer patients whose lymph nodes looked clear on routine staining, about 29% turned out to harbor cancer cells when re-examined with AE1/AE3.³ That kind of finding can change how a patient is staged and treated.

A similar approach is used in cervical cancer, where lymph nodes are analyzed with AE1/AE3 to look for micrometastases or isolated tumor cells that routine methods miss.⁴ The logic is the same: cytokeratin-expressing cells should not normally be in a lymph node. If AE1/AE3 highlights epithelial cells inside a node, the most likely explanation is that cancer cells migrated there from a primary tumor elsewhere.

The stain also plays a role when a patient has a metastatic deposit but nobody knows where the original cancer started. These cases are called cancers of unknown primary. Immunohistochemistry panels that include AE1/AE3 help narrow down the tissue of origin, and the diagnostic accuracy of these panels has improved significantly over the past decade.⁵ Again, AE1/AE3 is one piece of the puzzle, not the whole answer.

The False-Positive Problem

One of the real pitfalls of AE1/AE3 is that it can highlight cells that look suspicious but are not actually malignant. In a study of lymph nodes from patients with esophageal or gastric cancer, roughly one in five nodes that were negative on standard staining showed AE1/AE3-positive single cells that turned out not to have malignant characteristics. The specificity of AE1/AE3 in that context was about 84%, compared with 94% for a different antibody called Ber-Ep4.⁶ Those false-positive cells can be dendritic cells, macrophages, or other residents of the lymph node that weakly cross-react with the antibody cocktail.

A related issue comes up in Mohs surgery for skin cancer. Surgeons use AE1/AE3 staining on frozen tissue sections to check whether tumor margins are clear. But normal keratinocytes and certain benign structures in the skin also stain positive. Pathologists need to know the typical staining patterns of these harmless structures to avoid overcalling a positive result and removing more tissue than necessary.⁷ The stakes are practical: a false positive during surgery means the patient loses healthy tissue, while a false negative means cancer is left behind.

Cancers That Do Not Stain Positive

Just as AE1/AE3 positivity does not mean cancer, AE1/AE3 negativity does not rule it out. Several types of malignancy routinely fail to stain with this marker because they arise from cells that do not express cytokeratins. Melanomas, most sarcomas, and certain blood-cell cancers like plasma cell neoplasms are typically AE1/AE3-negative.⁸ If a pathologist suspects melanoma, a negative AE1/AE3 result is actually consistent with the diagnosis and prompts testing with melanoma-specific markers instead.

Small cell lung cancer, a particularly aggressive subtype, can also show variable cytokeratin expression, making AE1/AE3 less reliable for identifying it compared to other markers. The broader lesson is that no single immunohistochemical stain works as a universal cancer detector. Different cancers express different proteins, and the marker panel has to match the clinical suspicion.

Tumors That Stain Positive Unexpectedly

The relationship between AE1/AE3 and cell identity is not perfectly clean. Some non-epithelial tumors express cytokeratins even though they arise from cell types that normally do not. In one study of endometrial stromal sarcomas, a type of tumor originating from the connective tissue of the uterus rather than from epithelial cells, roughly half stained positive with AE1/AE3.⁹ The staining pattern had no correlation with tumor grade, meaning it was not a reliable indicator of how aggressive the cancer was.

A similar phenomenon has been reported in epithelioid hemangiosarcomas, vascular tumors that can mimic carcinomas under the microscope. In one series, about 43% of cases showed AE1/AE3 staining.¹⁰ When a tumor that is not supposed to be epithelial lights up with a pan-cytokeratin marker, it creates diagnostic confusion. A pathologist who relies on AE1/AE3 alone might misidentify the tumor as a carcinoma and point the clinical team toward the wrong treatment. These cases underscore why AE1/AE3 is always used alongside other markers, never as a standalone test.

How Pathologists Use AE1/AE3 in Practice

In modern diagnostic pathology, AE1/AE3 almost never appears by itself on a report. It is part of a panel of immunohistochemical markers chosen based on what the pathologist sees under the microscope and what the clinical scenario suggests. The stain’s primary value is as a sorting tool. Once AE1/AE3 confirms that the cells in question are epithelial, more targeted markers narrow the diagnosis. A panel might include markers for specific organs (like TTF-1 for lung or thyroid), specific tumor types (like synaptophysin for neuroendocrine tumors), or specific cellular lineages.

For Merkel cell carcinoma, a rare and aggressive skin cancer, researchers have found that a three-marker panel of SATB2, AE1/AE3, and synaptophysin catches virtually all lymph node metastases. Using SATB2 first detected about 89% of cases, and adding AE1/AE3 pushed the detection rate to 99%.¹¹ The key here is that no single marker was sufficient. It took a combination to achieve high accuracy.

A review of immunohistochemistry in soft tissue tumors put the broader principle bluntly: lineage-specific markers generally do not distinguish between benign and malignant growths. That distinction still has to be made by looking at the tissue structure, the cell appearance, and the clinical context.¹² An experienced pathologist integrates all of this information. The stain is a tool; the pathologist is the interpreter.

Distinguishing Between Different Diseases

One area where AE1/AE3 positivity is expected on both sides of the differential, making it less helpful for the key question, is the distinction between mesothelioma and lung adenocarcinoma. Both are malignancies, but they require very different treatment approaches. In a study comparing immunohistochemical markers between the two, AE1/AE3 stained 100% of both epithelioid mesotheliomas and lung adenocarcinomas.¹³ Since both diseases light up equally, AE1/AE3 cannot tell them apart. That job falls to other markers like calretinin and CEA, which show sharply different staining patterns between the two cancers.

Earlier work reached the same conclusion, finding that AE1/AE3 reacted with a high percentage of both mesothelioma and adenocarcinoma specimens, making it unhelpful for differentiating between the two.¹⁴ For patients whose pathology report shows AE1/AE3 positivity in a pleural biopsy, the stain confirms that the cells are epithelial but says nothing about which epithelial malignancy is present. The more informative markers are the ones that follow.

When AE1/AE3 Positivity Is Highly Specific

There are a few clinical scenarios where AE1/AE3 positivity carries more diagnostic weight. One instructive example involves brain tumors. Hemangioblastomas and metastatic clear-cell renal cell carcinomas can look strikingly similar under the microscope, but their treatment and prognosis are completely different. Research has shown that AE1/AE3 positivity in tumor cells is essentially the signature of a metastatic renal cell carcinoma in this setting, with 100% specificity and 88% sensitivity. Hemangioblastomas, by contrast, are AE1/AE3-negative. Combining AE1/AE3 with another marker called aquaporin-1, which is positive in hemangioblastomas and negative in renal metastases, allowed pathologists to distinguish between the two with about 97% accuracy in both directions.¹⁵

This is one of the rare contexts where a positive AE1/AE3 result, in combination with a specific clinical setting and one additional marker, comes close to answering a diagnostic question on its own. But even here, the answer depends on context: AE1/AE3 positivity means something very different in a brain tumor biopsy than it does in a breast biopsy or a lymph node.

What to Do If Your Pathology Report Shows AE1/AE3 Positive

If you are reading a pathology report and see “AE1/AE3 positive” listed among the immunohistochemistry results, the first thing to understand is that this finding is one data point in a larger picture. It tells your medical team that the cells in question express cytokeratins, which is expected for any epithelial tissue and for many epithelial cancers. It does not, on its own, confirm or rule out a cancer diagnosis.

The rest of the report matters far more for your actual diagnosis. The pathologist’s final interpretation will integrate the AE1/AE3 result with the tissue architecture, cell morphology, results from other immunohistochemical markers, and clinical information like where the biopsy was taken and what symptoms prompted it. If carcinoma is suspected, you will likely see additional markers on the report that narrow the tumor type and origin. If the cells look benign under the microscope, AE1/AE3 positivity is entirely unremarkable and simply confirms the epithelial nature of the tissue.

One practical point worth flagging: micrometastasis detection with AE1/AE3 can upstage a cancer, meaning it may move the diagnosis to a more advanced stage than what routine staining suggested. In the colorectal cancer study mentioned earlier, nearly a third of patients with apparently clear lymph nodes had hidden cancer cells revealed by this stain.³ Whether such findings change treatment decisions depends on the cancer type, the number and size of the deposits, and evolving clinical guidelines. These are conversations to have with your oncologist, who can put the pathology findings into the context of your specific case.

Why AE1/AE3 Testing Is Not Routine for Everyone

Given its ability to reveal hidden cancer cells, you might wonder why AE1/AE3 immunohistochemistry is not performed on every tissue sample. The answer comes down to when the extra information changes clinical decisions. In straightforward biopsies where the diagnosis is clear from standard staining, adding immunohistochemistry would increase cost and processing time without altering the outcome. The stain earns its place in ambiguous cases: when cells look unusual, when a tumor’s origin is unclear, when lymph nodes need closer scrutiny for micrometastases, or when the pathologist needs to distinguish between two diagnoses that look alike under the microscope but require different treatments.

There is also the issue of false positives. As we saw in the esophageal cancer lymph node study, about one in five AE1/AE3-positive cells in negative nodes turned out to lack malignant features.⁶ Applying the stain indiscriminately would generate ambiguous findings that could lead to unnecessary anxiety, additional biopsies, or overtreatment. Pathologists order it selectively, when the clinical question is specific enough that the result will genuinely inform the next step.

1
PubMed Central. Intermediate filaments: a role in epithelial polarity
2
PubMed. Structural distinctions among human breast epithelial cells revealed by the monclonal antikeratin antibodies AE1 and AE3
3
PubMed Central. Detection of lymph nodes micrometastases in Dukes’ A and B colorectal cancer using anti-cytokeratin antibodies AE1/AE3
4
International Journal of Gynecology & Obstetrics. Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence
5
PubMed Central. Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site
6
Diseases of the Esophagus. Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia
7
PubMed Central. Identifying squamous cell carcinoma and cytokeratin-derived amyloid with pan-cytokeratin AE1/AE3 during Mohs micrographic surgery
8
PubMed. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids
9
Human Pathology. Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma
10
PubMed Central. Cytokeratin AE1/AE3 immunolabeling in epithelioid hemangiosarcoma
11
PubMed Central. SATB2, CKAE1/AE3, and synaptophysin as a sensitive immunohistochemical panel for the detection of lymph node metastases of Merkel cell carcinoma
12
PubMed Central. Immunohistochemistry of soft tissue tumours – review with emphasis on 10 markers
13
PubMed. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
14
Cancer. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma
15
The American Journal of Surgical Pathology. Immunohistochemical Markers to Distinguish Between Hemangioblastoma and Metastatic Clear-cell Renal Cell Carcinoma in the Brain: Utility of Aquaporin1 Combined With Cytokeratin AE1/AE3 Immunostaining